Dyspepsia is a chronic medical condition which causes discomfort in the upper abdomen as a result of indigestion. The stomach and the small intestine, and sometimes the esophagus does not function properly which is the main reason for the discomfort. Gastritis, peptic ulcers, gallstones, stomach cancer, constipation, reduced blood flow in the intestine are other causes for dyspepsia. Overeating, over-consumption of alcohol and smoking, might also cause dyspepsia. The global dyspepsia market is perceived to be a steadily growing market as per the analysis of market Research Future (MRFR).
Market Research Future has starting late imparted another examination to its wide research portfolio, which is titled as “Dyspepsia Market Research Report – Forecast to 2023″ gives an all-around examination the measure of market size and advancements
Surging prevalence of digestive diseases across the globe is one of the prime reasons for the growth of the global dyspepsia market. The Centers for Disease Control and Prevention estimated 14.7 Mn people in the US to be suffering from digestive ulcers in 2016. Also, the American Cancer Society projected 26,240 new cases of stomach cancer to be diagnosed in the year 2018. The rise in the global geriatric population remains a significant growth driver. The aged populace is generally more susceptible to digestive disorders and induces high demand for diagnosis treatment.
Other factors boosting the growth of the market include the growing occurrence of diabetes and thyroid among the global population. Rigorous RD activities to develop new drugs and therapies are also likely to augur the growth of the market over the forecast period. Unhealthy diet and a sedentary lifestyle can also be considered as a major reason for the growth of the global dyspepsia market. Due to the current busy lifestyle, consumers are more prone to consuming on-the-go food items which are generally unhealthy and cause digestive disorders.
Additionally, such a situation is worsened by smoking and alcohol consumption which favors market growth. On the flipside, the growth of the market might be hindered by high costs associated with diagnostic tests and cut-throat competition among market players.
The global dyspepsia market has been segmented based on diagnosis, treatment, and end user.
By diagnosis, the global dyspepsia market has been segmented into blood tests, breath tests, stool tests, endoscopy, X-ray, CT scan, and others.
By treatment, the global dyspepsia market has been segmented into antacids, antibiotics, h2 blockers, proton pump inhibitors (PPIs), prokinetics, psychological therapies, and others. The antacids segment has been further segmented into calcium carbonate, loperamide, simethicone, sodium bicarbonate, and others. The antibiotic segment has been further segmented into amoxicillin, clarithromycin, metronidazole, and others.
The H2 blockers segment has been further segmented into cimetidine, famotidine, nizatidine, ranitidine, and others. The Proton pump inhibitors (PPIs) segment has been further segmented into esomeprazole, lansoprazole, and omeprazole. Prokinetics are categorized into bethanechol and metoclopramide.
By end user, the global dyspepsia market has been segmented into hospitals and clinics, ambulatory surgical centers, pharmacies, diagnostic centers, and others.
By region, the global dyspepsia market has been segmented into the Americas, Europe, Asia-Pacific (APAC), and the Middle East and Africa (MEA).
The notable players in the global dyspepsia market are
- Allergan Plc,
- Takeda Pharmaceutical Company,
- Abbott Laboratories,
- Johnson Johnson,
- Eisai Co., Ltd.,
- Bayer AG,
- Salix Pharmaceuticals,
- Boehringer Ingelheim GmbH